Wěi Li

72.4k total citations · 12 hit papers
1.4k papers, 44.8k citations indexed

About

Wěi Li is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Wěi Li has authored 1.4k papers receiving a total of 44.8k indexed citations (citations by other indexed papers that have themselves been cited), including 567 papers in Molecular Biology, 356 papers in Oncology and 202 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Wěi Li's work include Lung Cancer Treatments and Mutations (79 papers), HER2/EGFR in Cancer Research (71 papers) and Synthesis and biological activity (65 papers). Wěi Li is often cited by papers focused on Lung Cancer Treatments and Mutations (79 papers), HER2/EGFR in Cancer Research (71 papers) and Synthesis and biological activity (65 papers). Wěi Li collaborates with scholars based in China, United States and Australia. Wěi Li's co-authors include Duane D. Miller, Andrzej Słomiński, Robert C. Tuckey, Chunlei Liu, Tae‐Kang Kim, Jianjun Chen, Bing Wu, Yan Lü, Zorica Janjetović and Jin Wang and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Wěi Li

1.4k papers receiving 44.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Wěi Li et al. profile →
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

2014 1.6k citations Jifeng Feng, Wěi Li et al. profile →
HIF-1α pathway: role, regulation and intervention for cancer therapy

2015 1.4k citations Wěi Li et al. profile →
An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site

2012 626 citations Jianjun Chen, Wěi Li et al. profile →
Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition

2011 503 citations Wěi Li et al. profile →
Suppression of cancer relapse and metastasis by inhibiting cancer stemness

2015 382 citations Wěi Li et al. profile →
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

2015 324 citations Wěi Li et al. profile →
Antibody–drug conjugates: Recent advances in payloads

2023 130 citations Wěi Li, Yuxi Wang et al. profile →
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

2024 56 citations Wei Wang, Najah Albadari et al. Pharmacological Reviews profile →
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

2024 53 citations Wěi Li et al. profile →
Biological Effects of CYP11A1-Derived Vitamin D and Lumisterol Metabolites in the Skin

2024 45 citations Wěi Li et al. profile →
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

2025 16 citations Xiaojia Wang, Wěi Li et al. profile →

Peers

Countries citing papers authored by Wěi Li

Since Specialization

Citations

This map shows the geographic impact of Wěi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wěi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wěi Li more than expected).

Fields of papers citing papers by Wěi Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wěi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wěi Li. The network helps show where Wěi Li may publish in the future.

Co-authorship network of co-authors of Wěi Li

This figure shows the co-authorship network connecting the top 25 collaborators of Wěi Li. A scholar is included among the top collaborators of Wěi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wěi Li. Wěi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of TRPC3 channels suppresses seizure susceptibility in the genetically-epilepsy prone rats 2024 ·European Journal of Pharmacology ·(unknown), (unknown), Wěi Li, Prosper N’Gouemo	2
2	MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future breakdown → 2024 ·Pharmacological Reviews ·Wei Wang, Najah Albadari, (unknown), (unknown), (unknown), Wa Xian, Frank McKeon, Wěi Li, Jia Zhou, Ruiwen Zhang	56
3	Lineage 1 PRRSVs infection induces hemorrhagic injury in intestines of piglets: Effects on complement and coagulation cascades 2024 ·Microbial Pathogenesis ·Yongxin Zhao, (unknown), Wěi Li, (unknown), (unknown), (unknown), Xiaoli Zhang, Jingnan Zhang, Junda Li, (unknown), (unknown), (unknown), (unknown), Basit Zeshan, Yefei Zhou, Xinglong Wang	2
4	Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy 2023 ·PubMed ·Xiaojia Wang, Wěi Li, Yongmei Yin, Zhongsheng Tong, Qingyuan Zhang, Hong Zheng, (unknown), Huiping Li, Yang Jin, Jifeng Feng, Fan Wu, (unknown), Eleonora Restuccia, Zefei Jiang	4
5	Occurrence and fate characteristics of isoproturon from garlic cultivation to household processing: Implication for human exposure 2023 ·Journal of Hazardous Materials ·(unknown), Li Li, Xin Ren, Minghao Zhang, Wěi Li, Zenglong Chen	9
6	Enantiomeric N-acetyldopamine trimers from Cicadae Periostracum and their absolute configurations 2023 ·Phytochemistry ·Mei Fang, (unknown), Wen Yan, Zhenwei Li, (unknown), Li‐She Gan, Wěi Li, De‐an Guo	4
7	In silico design of a broad-spectrum multiepitope vaccine against influenza virus 2023 ·International Journal of Biological Macromolecules ·Lifang Yuan, Xu Li, Minchao Li, (unknown), Yingrui Li, (unknown), Wěi Li, (unknown), Huanle Luo, Caijun Sun, Yuelong Shu	12
8	Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study 2020 ·Clinical Cancer Research ·Ligang Xing, Yueyin Pan, Yuankai Shi, Yongqian Shu, Jifeng Feng, Wěi Li, Lejie Cao, Lifeng Wang, Wei Gu, Yong Song, Puyuan Xing, Yutao Liu, Wen Gao, Jiuwei Cui, (unknown), Rutian Li, Hua Bao, Yang Shao, Jinming Yu	28
9	Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor 2019 ·Molecular Cancer Therapeutics ·Guannan Zhao, Qinghui Wang, Zhongzhi Wu, Xinchun Tian, Huan Yan, (unknown), Peixin Dong, Hidemichi Watari, Lawrence M. Pfeffer, Yuqi Guo, Wěi Li, Junming Yue	33
10	A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance 2017 ·Cancer Research ·Kinsie E. Arnst, Yuxi Wang, Dong‐Jin Hwang, Yi Xue, (unknown), David J. Hamilton, Qiang Chen, Jinliang Yang, Frank Park, James T. Dalton, Duane D. Miller, Wěi Li	100
11	A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity 2016 ·Molecular Cancer Therapeutics ·Michael L. Miller, Nathan Fishkin, Wěi Li, Kathleen R. Whiteman, Yelena Kovtun, (unknown), Katie E. Archer, Erin K. Maloney, Charlene A. Audette, Michele Mayo, Alan Wilhelm, (unknown), Rajeeva Singh, Jan Pinkas, Victor S. Goldmacher, John M. Lambert, Ravi Chari	65
12	Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis 2015 ·Cancer Prevention Research ·Hayato Hikita, Takahiro Kodama, Satoshi Tanaka, Yoshinobu Saito, Yasutoshi Nozaki, Tasuku Nakabori, Satoshi Shimizu, Yoshito Hayashi, Wěi Li, Minoru Shigekawa, Ryotaro Sakamori, Takuya Miyagi, Naoki Hiramatsu, Tomohide Tatsumi, Tetsuo Takehara	20
13	Caffeic Acid Directly Targets ERK1/2 to Attenuate Solar UV-Induced Skin Carcinogenesis 2014 ·Cancer Prevention Research ·Ge Yang, Yang Fu, Margarita Malakhova, Igor Kurinov, Feng Zhu, Ke Yao, Haitao Li, Hanyong Chen, Wěi Li, Do Young Lim, Yuqiao Sheng, Ann M. Bode, Ziming Dong, Zigang Dong	47
14	Whole Transcriptome Sequencing Reveals Extensive Unspliced mRNA in Metastatic Castration-Resistant Prostate Cancer 2014 ·Molecular Cancer Research ·Adam G. Sowalsky, Zheng Xia, Liguo Wang, Hao Zhao, Shaoyong Chen, Glenn J. Bubley, Steven P. Balk, Wěi Li	84
15	Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma 2013 ·Molecular Cancer Therapeutics ·Jin Wang, Jianjun Chen, Duane D. Miller, Wěi Li	26
16	A Sequence Polymorphism in miR-608 Predicts Recurrence after Radiotherapy for Nasopharyngeal Carcinoma 2013 ·Cancer Research ·Jian Zheng, Jieqiong Deng, Mang Xiao, Lei Yang, Liyuan Zhang, Yonghe You, Min Hu, Na Li, Hongchun Wu, Wěi Li, Jiachun Lü, Yifeng Zhou	49
17	Loss of miR-204 Expression Enhances Glioma Migration and Stem Cell-like Phenotype 2012 ·Cancer Research ·Zhe Ying, Yun Li, Jueheng Wu, Xun Zhu, Yi Yang, Han Tian, Wěi Li, Bo Hu, Shi‐Yuan Cheng, Mengfeng Li	129
18	Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer 2011 ·Cancer Research ·Chunpeng Zhang, Liguo Wang, Dayong Wu, Hongyan Chen, Zhong Chen, Jennifer M. Thomas‐Ahner, Debra L. Zynger, Jérôme Eeckhoute, Jindan Yu, Jun Luo, Myles Brown, Steven K. Clinton, Kenneth P. Nephew, Tim H.‐M. Huang, Wěi Li, Qianben Wang	73
19	Pegylated Kunitz Domain Inhibitor Suppresses Hepsin-Mediated Invasive Tumor Growth and Metastasis 2009 ·Cancer Research ·Wěi Li, Bu-Er Wang, Paul Moran, Terry Lipari, Rajkumar Ganesan, Racquel Corpuz, Mary J. C. Ludlam, Alvin Gogineni, Hartmut Koeppen, Stuart Bunting, Wei‐Qiang Gao, Daniel Kirchhofer	44
20	The Asn418-Linked N -Glycan of ErbB3 Plays a Crucial Role in Preventing Spontaneous Heterodimerization and Tumor Promotion 2007 ·Cancer Research ·Shunichi Yokoe, Motoko Takahashi, Michio Asahi, Seung Ho Lee, Wěi Li, (unknown), Eiji Miyoshi, Naoyuki Taniguchi	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact